The Technical Analyst
Biomx Inc [PHGE]
Exchange: AMEX Sector: Healthcare Industry: Biotechnology
Biomx Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
-0.07% $0.280
America/New_York / 17 apr 2024 @ 15:55
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 15.47 mill |
| EPS: | -0.510 |
| P/E: | -0.550 |
| Earnings Date: | May 10, 2024 |
| SharesOutstanding: | 55.22 mill |
| Avg Daily Volume: | 2.65 mill |
| RATING 2024-04-17 |
|---|
| B |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Sell | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Strong Buy | |
| P/E: | Neutral | |
| Price To Book: | Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | |||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.550 | sector: PE -4.07 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 0x |
| Company: PE -0.550 | industry: PE -5.55 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$-0.133 (-147.40%) $-0.413 |
| Date: 2024-04-17 |
| Expected Trading Range (DAY) |
|---|
|
$ 0.225 - 0.335 ( +/- 19.64%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-04-11 | Blum Susan | Buy | 0 | |
| 2024-03-16 | Cystic Fibrosis Foundation | Sell | 0 | Common Stock, par value $0.0001 per share |
| 2024-03-16 | Cystic Fibrosis Foundation | Sell | 21 635 000 | Series X Preferred Stock |
| 2024-03-16 | Cystic Fibrosis Foundation | Sell | 10 817 500 | Warrant to purchase common stock |
| 2024-03-16 | Cystic Fibrosis Foundation | Sell | 4 778 265 | Warrant to purchase common stock |
| INSIDER POWER |
|---|
| -67.56 |
| Last 91 transactions |
| Buy: 9 333 285 | Sell: 39 545 482 |
Forecast:
16:00 - $0.280
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $0.280
Forecast 2: 16:00 - $0.280
Forecast 3: 16:00 - $0.280
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $0.280 (-0.07% ) |
| Volume | 0.128 mill |
| Avg. Vol. | 2.65 mill |
| % of Avg. Vol | 4.83 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For PHGE
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
PHGE
BiomX Inc., a clinical-stage microbiome company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria. It targets bacteria that affect the appearance of skin, as well as chronic diseases, such as inflammatory bowel diseases (IBD), primary sclerosing cholangitis (PSC), cystic fibrosis (CF), atopic dermatitis, and colorectal cancer (CRC). It is developing BX004, a phage therapy for CF patients with chronic Pseudomonas aeruginosa respiratory infections that is in Phase 1b/2a clinical trials. The company's pipeline products also include BX005, a topical phage cocktail, which is in Phase 1/2 clinical study that targets Staphylococcus aureus (S. aureus), a bacteria associated with the manifestation of the disease; and BX003, an orally administered phage cocktail, which is in Phase 1b/2a that targets a bacterial target present in the gut of IBD and PSC patients. In addition, the company engages in the provision of colorectal cancer program that utilizes engineered phage with various payloads, which are administered intravenously to target Fusobacterium nucleatum bacteria residing within the tumor microenvironment. BiomX Inc. was founded in 2015 and is headquartered in Ness Ziona, Israel.
Latest Press Releases
2024-04-04 07:49:00 - Press Release
Biomx Announces Compliance With Nyse Guidelines On Audit Opinion Disclosure
Cambridge, mass. and ness ziona, israel, april 04, 2024 (globe newswire) -- biomx inc. (nyse american: phge) (“biomx”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that, as previously disclosed in its annual report on form 10-k for the fiscal year ended december 31, 2023, which was filed with the securities and exchange commission on april 4, 2024, the audit opinion contained a going concern qualification from the company's independent registered public accounting firm. this announcement is being made solely to comply with the nyse american company guide sections 401(h) and 610(b), which require separate disclosure of receipt of an audit opinion that contains a going concern qualification...
2024-04-03 06:30:00 - Press Release
Biomx Reports Fourth Quarter And Full Year 2023 Financial Results And Provides Business Update
Recent acquisition of adaptive phage therapeutics creates leader in phage therapy with advanced, clinical-stage pipeline
2024-03-27 06:30:00 - Press Release
Biomx To Host Fourth Quarter And Full Year 2023 Financial Results Conference Call And Webcast On April 3rd, 2024
Cambridge, mass. and ness ziona, israel, march 27, 2024 (globe newswire) -- biomx inc. (nyse american: phge) (“biomx” or the “company”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that the company will host a conference call and a live audio webcast on wednesday, april 3rd, 2024, at 8:00 a.m. et, to report fourth quarter and full year 2023 financial results and a provide business update.
2024-03-18 06:30:00 - Press Release
Biomx Announces Closing Of The Acquisition Of Adaptive Phage Therapeutics And Concurrent $50 Million Financing
Acquisition creates leading phage therapy company with an advanced pipeline that includes two phase 2 assets, bx004 for the treatment of chronic pulmonary infections in cystic fibrosis (“cf”) patients and bx211 for the treatment of diabetic foot osteomyelitis (“dfo”)
2024-03-07 03:45:00 - Press Release
Shareholder Alert: Ademi Llp Investigates The Transaction Between Biomx Inc. And Adaptive Phage Therapeutics
Milwaukee , march 7, 2024 /prnewswire/ -- ademi llp is investigating biomx (nyse american: phge) for possible breaches of fiduciary duty and other violations of law in its transaction with adaptive phage therapeutics. click here to learn how to join the https://www.ademilaw.com/case/biomx-inc or call guri ademi toll-free at 866-264-3995.
Latest News
2024-04-05 10:56:04 - Zacks Investment Research
Here's Why BiomX (PHGE) Is a Great 'Buy the Bottom' Stock Now
BiomX (PHGE) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
2024-04-03 12:26:10 - Seeking Alpha
BiomX Inc. (PHGE) Q4 2023 Earnings Call Transcript
BiomX Inc. (NYSE:PHGE ) Q4 2023 Earnings Conference Call April 3, 2024 8:00 AM ET Company Participants Avi Gabay - Interim CFO Jonathan Solomon - CEO Conference Call Participants Joseph Pantginis - H.C. Wainwright Operator Good morning, and welcome to the BiomX Full Year 2023 Financial Results and Corporate Update Conference Call.
2024-03-27 06:30:00 - GlobeNewsWire
BiomX to Host Fourth Quarter and Full Year 2023 Financial Results Conference Call and Webcast on April 3rd, 2024
CAMBRIDGE, Mass. and NESS ZIONA, Israel, March 27, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that the Company will host a conference call and a live audio webcast on Wednesday, April 3rd, 2024, at 8:00 a.m. ET, to report fourth quarter and full year 2023 financial results and a provide business update.
2024-03-06 11:52:24 - InvestorPlace
Why Is BiomX (PHGE) Stock Up 147% Today?
BiomX (NYSEMKT: PHGE ) stock is rocketing higher on Wednesday after announcing merger plans with privately-held clinical-stage biotechnology company Adaptive Phage Therapeutics. This will have the clinical-stage microbiome company combining with Adaptive Phage Therapeutics within the next 30 days.
2023-12-04 06:46:08 - Zacks Investment Research
BiomX (PHGE) Reports Positive Pulmonary Infection Treatment Data
BiomX's (PHGE) BX004 showcases an impressive 14% conversion to a negative P. aeruginosa sputum culture at the end of treatment.
2023-11-23 07:43:09 - Seeking Alpha
BiomX: BX004 Phage Cocktail Part 2, Phase 1b/2a Clinical Results In Cystic Fibrosis Expected Any Day
BiomX announced positive results from Part 1 of its Phase 1b/2a study for its novel phage cocktail, BX004, treating chronic pulmonary infections caused by P. aeruginosa bacteria in Cystic Fibrosis. Part 1 study was small (N=9), double-blind, BX004 therapeutic showed notable reductions in bacterial burden in cystic fibrosis. Published compassionate use of Phage treatment at Yale in CF is also encouraging. The larger Part 2 Phase 2a of this clinical study has been completed and results will be released any day.
2023-10-27 08:00:00 - GlobeNewsWire
BiomX to Present Data from Ongoing Phase 1b/2a Study Evaluating BX004 for the Treatment of Chronic Pseudomonas aeruginosa Pulmonary Infections in Patients with Cystic Fibrosis at the 37th Annual North American Cystic Fibrosis Conference
CAMBRIDGE, Mass. and NESS ZIONA, Israel, Oct. 27, 2023 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that the Company will present data from Part 1 of its ongoing Phase 1b/2a study evaluating the novel phage product candidate, BX004, for the treatment of chronic Pseudomonas a eruginosa (PsA) pulmonary infections in people with cystic fibrosis (“CF”) at the 37th Annual North American Cystic Fibrosis Conference, which is being held November 2-4, 2023, in Phoenix, Arizona. The abstract was selected for an oral presentation at the conference.
2023-08-02 16:30:00 - GlobeNewsWire
BiomX to Host Second Quarter 2023 Financial Results Conference Call and Webcast on August 9th, 2023
CAMBRIDGE, Mass. and NESS ZIONA, Israel, Aug. 02, 2023 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that the Company will host a conference call and a live audio webcast on Wednesday, August 9th, 2023, at 8:00 a.m. ET, to report second quarter 2023 financial results and provide business updates.
2023-05-31 03:00:00 - GlobeNewsWire
BiomX to Present Part 1 Data from Phase 1b/2a Study Evaluating BX004 for the Treatment of Chronic Pseudomonas aeruginosa Pulmonary Infections in Patients with Cystic Fibrosis During Late-Breaking Science Session at the 46th European Cystic Fibrosis Conference (ECFC)
CAMBRIDGE, Mass. and NESS ZIONA, Israel, May 31, 2023 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that the Company will present Part 1 data from its ongoing Phase 1b/2a study evaluating the novel phage product candidate, BX004, for the treatment of chronic Pseudomonas a eruginosa (PsA) pulmonary infections in patients with cystic fibrosis (“CF”) during the Late-Breaking Science Session at 46th European Cystic Fibrosis Conference (ECFC), which is being held June 7-10th, 2023, in Vienna, Austria.
2023-05-12 07:48:19 - InvestorPlace
Why Is BiomX (PHGE) Stock Up 10% Today?
BiomX (NYSEMKT: PHGE ) stock is on the rise Friday as investors prepare for the clinical-stage company to release its latest earnings report on Monday. That means investors will want to check in on the company early as it plans to release its Q1 report before markets open.